CD22

Summary

CD22 (CD22 molecule, HGNC:1643) is a protein-coding gene on chromosome 19q13.12, encoding B-cell receptor CD22 (P20273). Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow.

Predicted to enable CD4 receptor binding activity; protein phosphatase binding activity; and sialic acid binding activity. Involved in B cell activation; negative regulation of B cell receptor signaling pathway; and regulation of endocytosis. Located in early endosome and recycling endosome. Implicated in diffuse large B-cell lymphoma.

Source: NCBI Gene 933 — automated summary from GO annotations (Alliance of Genome Resources).

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 149 total — 1 pathogenic
• GTEx eGene: eQTL in 35 tissues, sQTL in 14 (q < 0.05)
• Drug target: yes — 13 curated mechanism-of-action drugs
• Approved drugs (ChEMBL mechanism of action): 2 — Inotuzumab Ozogamicin, Moxetumomab Pasudotox
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.64 (unconstrained)
• MANE Select transcript: NM_001771
• Interaction hub: 1,766 STRING partners (top 10% of genes corpus-wide)
• Notable: 149 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1643
Approved symbol	CD22
Name	CD22 molecule
Location	19q13.12
Locus type	gene with protein product
Status	Approved
Aliases	SIGLEC-2, SIGLEC2
Ensembl gene	ENSG00000012124
Ensembl biotype	protein_coding
OMIM	107266
Entrez	933

Gene structure

Transcript identifiers

Ensembl transcripts: 41 — 21 protein_coding, 9 protein_coding_CDS_not_defined, 7 retained_intron, 4 nonsense_mediated_decay

MANE Select: ENST00000085219

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 5, TSL 2: 2, TSL 3: 8, TSL 4: 11, TSL 5: 7

ENST00000085219, ENST00000341773, ENST00000419549, ENST00000536635, ENST00000544992, ENST00000593704, ENST00000593867, ENST00000594125, ENST00000594250, ENST00000594349, ENST00000594954, ENST00000595419, ENST00000595780, ENST00000596492, ENST00000597433, ENST00000597916, ENST00000598028, ENST00000598138, ENST00000598537, ENST00000598815, ENST00000599717, ENST00000599799, ENST00000599811, ENST00000600131, ENST00000600424, ENST00000600655, ENST00000600905, ENST00000601329, ENST00000601414, ENST00000601732, ENST00000601769, ENST00000602123, ENST00000602224, ENST00000613136, ENST00000884225, ENST00000884226, ENST00000884227, ENST00000884228, ENST00000918678, ENST00000948629, ENST00001142920

RefSeq mRNA: 5 — MANE Select: NM_001771 NM_001185099, NM_001185100, NM_001185101, NM_001278417, NM_001771

CCDS: CCDS12457, CCDS54247, CCDS54248, CCDS54249, CCDS62634

Canonical transcript exons

ENST00000085219 — 14 exons

Exon	Start	End
ENSE00003006937	35329187	35329230
ENSE00003528089	35344829	35344925
ENSE00003528304	35346151	35346235
ENSE00003529118	35337755	35338021
ENSE00003546049	35338168	35338431
ENSE00003602356	35345602	35345720
ENSE00003630859	35341702	35341965
ENSE00003632030	35340881	35341138
ENSE00003651873	35332019	35332074
ENSE00003652433	35336036	35336341
ENSE00003675894	35341343	35341606
ENSE00003691466	35345051	35345126
ENSE00003751072	35332547	35332924
ENSE00004801882	35346566	35347361

Expression profiles

Bgee: expression breadth ubiquitous, 219 present calls, max score 97.88.

FANTOM5 (CAGE): breadth broad, TPM avg 8.0214 / max 693.0678, expressed in 370 samples.

Highest expression (Bgee): spleen, ovary, vermiform appendix, C1 segment of cervical spinal cord, lymph node.

Genetic regulation across tissues (GTEx eQTL / sQTL)

CD22 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 35 tissues and its splicing (sQTL) in 14 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 49 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Thyroid	eqtl	1.5e-90	-1.01	19:35309759:G:T
Pituitary	eqtl	2.8e-68	-1.11	19:35309759:G:T
Cells EBV-transformed lymphocytes	sqtl	1.3e-55	+1.64	19:35345867:G:A
Spleen	sqtl	1.0e-54	+1.33	19:35345867:G:A
Heart Atrial Appendage	eqtl	3.8e-53	-1.11	19:35309759:G:T
Colon Sigmoid	eqtl	6.6e-46	-0.90	19:35309759:G:T
Artery Tibial	eqtl	4.8e-44	-0.66	19:35309759:G:T
Lung	eqtl	1.3e-42	-0.78	19:35309759:G:T
Adrenal Gland	eqtl	3.7e-38	-1.07	19:35309759:G:T
Prostate	eqtl	7.7e-34	-0.83	19:35309759:G:T
Pancreas	eqtl	3.4e-33	-1.10	19:35309759:G:T
Muscle Skeletal	eqtl	2.2e-24	-0.59	19:35309759:G:T
Heart Left Ventricle	eqtl	6.2e-24	-0.70	19:35309759:G:T
Liver	eqtl	7.7e-23	-0.96	19:35309759:G:T
Adipose Visceral Omentum	eqtl	3.1e-22	-0.51	19:35309759:G:T
Breast Mammary Tissue	eqtl	4.4e-22	-0.67	19:35309759:G:T
Nerve Tibial	eqtl	1.4e-18	+0.29	19:35277925:T:C
Whole Blood	sqtl	8.2e-18	-0.57	19:35345848:A:G
Uterus	eqtl	2.6e-15	-1.06	19:35309759:G:T
Artery Aorta	eqtl	1.8e-12	-0.46	19:35309759:G:T

FANTOM5 promoters

9 alternative TSS:

Promoter ID	TPM avg	Samples expressed
175316	6.6647	200
175305	1.1567	254
175306	0.0621	28
175312	0.0597	14
175315	0.0222	11
175314	0.0171	6
175310	0.0159	7
175311	0.0146	6
175313	0.0084	6

Top tissues by expression

showing 100 of 286 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
spleen	UBERON:0002106	97.88	gold quality
left ovary	UBERON:0002119	97.21	gold quality
vermiform appendix	UBERON:0001154	97.19	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.77	gold quality
lymph node	UBERON:0000029	96.74	gold quality
right uterine tube	UBERON:0001302	96.31	gold quality
granulocyte	CL:0000094	96.27	gold quality
right ovary	UBERON:0002118	95.93	gold quality
sural nerve	UBERON:0015488	94.45	gold quality
spinal cord	UBERON:0002240	94.21	gold quality
ovary	UBERON:0000992	94.17	gold quality
caecum	UBERON:0001153	92.92	gold quality
corpus callosum	UBERON:0002336	92.81	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	91.05	gold quality
putamen	UBERON:0001874	90.28	gold quality
inferior olivary complex	UBERON:0002127	90.24	gold quality
caudate nucleus	UBERON:0001873	89.62	gold quality
amygdala	UBERON:0001876	88.99	gold quality
substantia nigra	UBERON:0002038	88.81	gold quality
blood	UBERON:0000178	88.66	gold quality
middle frontal gyrus	UBERON:0002702	88.63	gold quality
Ammon’s horn	UBERON:0001954	87.66	gold quality
ileal mucosa	UBERON:0000331	87.55	gold quality
ileum	UBERON:0002116	87.47	silver quality
midbrain	UBERON:0001891	87.40	gold quality
Brodmann (1909) area 9	UBERON:0013540	86.81	gold quality
right frontal lobe	UBERON:0002810	86.78	gold quality
endometrium epithelium	UBERON:0004811	85.88	gold quality
small intestine Peyer’s patch	UBERON:0003454	85.87	gold quality
medial globus pallidus	UBERON:0002477	85.74	gold quality
nucleus accumbens	UBERON:0001882	85.70	gold quality
pancreatic ductal cell	CL:0002079	85.50	silver quality
buccal mucosa cell	CL:0002336	85.21	silver quality
epithelium of nasopharynx	UBERON:0001951	85.20	gold quality
type B pancreatic cell	CL:0000169	85.10	gold quality
hypothalamus	UBERON:0001898	85.06	gold quality
adrenal tissue	UBERON:0018303	84.54	gold quality
tonsil	UBERON:0002372	84.14	gold quality
olfactory bulb	UBERON:0002264	84.10	silver quality
globus pallidus	UBERON:0001875	84.09	gold quality
cranial nerve II	UBERON:0000941	83.73	gold quality
tibial nerve	UBERON:0001323	83.42	gold quality
telencephalon	UBERON:0001893	83.27	gold quality
small intestine	UBERON:0002108	83.00	gold quality
inferior vagus X ganglion	UBERON:0005363	82.99	gold quality
temporal lobe	UBERON:0001871	82.75	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.53	gold quality
Brodmann (1909) area 46	UBERON:0006483	82.41	gold quality
rectum	UBERON:0001052	82.22	gold quality
bone marrow cell	CL:0002092	81.81	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	81.52	gold quality
forebrain	UBERON:0001890	81.47	gold quality
endothelial cell	CL:0000115	81.43	silver quality
frontal cortex	UBERON:0001870	81.39	gold quality
cingulate cortex	UBERON:0003027	81.36	gold quality
superficial temporal artery	UBERON:0001614	81.25	gold quality
anterior cingulate cortex	UBERON:0009835	81.14	gold quality
cerebral cortex	UBERON:0000956	80.95	gold quality
CA1 field of hippocampus	UBERON:0003881	80.70	gold quality
central nervous system	UBERON:0001017	80.61	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.58	gold quality
prefrontal cortex	UBERON:0000451	80.49	gold quality
bone marrow	UBERON:0002371	80.37	gold quality
brain	UBERON:0000955	80.17	gold quality
neocortex	UBERON:0001950	80.04	gold quality
gall bladder	UBERON:0002110	79.51	gold quality
postcentral gyrus	UBERON:0002581	79.18	gold quality
germinal epithelium of ovary	UBERON:0001304	79.17	silver quality
fallopian tube	UBERON:0003889	79.11	gold quality
colonic epithelium	UBERON:0000397	78.74	gold quality
mucosa of transverse colon	UBERON:0004991	78.65	gold quality
parietal lobe	UBERON:0001872	78.04	gold quality
leukocyte	CL:0000738	78.02	gold quality
upper lobe of left lung	UBERON:0008952	77.98	gold quality
islet of Langerhans	UBERON:0000006	77.75	gold quality
subthalamic nucleus	UBERON:0001906	77.57	gold quality
primary visual cortex	UBERON:0002436	77.54	gold quality
left adrenal gland cortex	UBERON:0035825	77.46	gold quality
frontal pole	UBERON:0002795	77.20	gold quality
paraflocculus	UBERON:0005351	77.19	gold quality
superior frontal gyrus	UBERON:0002661	77.01	gold quality
upper lobe of lung	UBERON:0008948	76.96	gold quality
Brodmann (1909) area 10	UBERON:0013541	76.95	gold quality
medulla oblongata	UBERON:0001896	76.91	gold quality
dorsal plus ventral thalamus	UBERON:0001897	76.77	gold quality
occipital lobe	UBERON:0002021	76.66	gold quality
mononuclear cell	CL:0000842	76.57	gold quality
monocyte	CL:0000576	76.44	gold quality
adrenal cortex	UBERON:0001235	76.26	gold quality
adrenal gland	UBERON:0002369	76.18	gold quality
right adrenal gland	UBERON:0001233	76.08	gold quality
orbitofrontal cortex	UBERON:0004167	75.91	gold quality
left adrenal gland	UBERON:0001234	75.53	gold quality
right adrenal gland cortex	UBERON:0035827	75.15	gold quality
thymus	UBERON:0002370	75.09	silver quality
parotid gland	UBERON:0001831	74.84	gold quality
ventral tegmental area	UBERON:0002691	74.67	gold quality
left uterine tube	UBERON:0001303	74.48	gold quality
oviduct epithelium	UBERON:0004804	74.43	gold quality
right hemisphere of cerebellum	UBERON:0014890	74.31	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 11.

Experiment	Marker?	Max mean expression
E-HCAD-32	yes	400.35
E-MTAB-8498	yes	150.07
E-HCAD-4	yes	116.07
E-CURD-122	yes	99.06
E-CURD-88	yes	47.04
E-ANND-3	yes	38.94
E-MTAB-9221	yes	22.17
E-MTAB-9067	yes	18.60
E-CURD-112	yes	10.23
E-MTAB-5061	yes	4.56
E-MTAB-9801	yes	3.81

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 73 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Tonsil	tissue	215.0	high
Lymph node	tissue	204.6	medium
Spleen	tissue	103.3	high
Ovary	tissue	88.3	not detected
Appendix	tissue	70.9	medium
Nucleus accumbens	tissue	58.0
Locus coeruleus	tissue	35.2
Hippocampus	tissue	33.9	not detected
Fallopian tube	tissue	29.0	not detected
Postcentral gyrus	tissue	14.6
Bone marrow	tissue	12.8	not detected
Thymus	tissue	10.6
Lung	tissue	7.0	not detected
Choroid plexus	tissue	6.7
Stomach 1	tissue	6.5	not detected
Small intestine	tissue	6.1	not detected
Rectum	tissue	6.0	not detected
Urinary bladder	tissue	5.3	not detected
Colon	tissue	4.6	not detected
Adrenal gland	tissue	4.2	not detected
Gallbladder	tissue	3.9	not detected
Endometrium 1	tissue	3.5	not detected
Spinal cord	tissue	3.4
Salivary gland	tissue	3.3	not detected
Testis	tissue	2.8	medium
Cervix	tissue	2.6	not detected
Adipose tissue	tissue	2.5	not detected
Substantia nigra	tissue	2.4
Epididymis	tissue	2.3	not detected
Duodenum	tissue	2.2	not detected
Corpus callosum	tissue	2.2
Prostate	tissue	2.2	not detected
Medulla oblongata	tissue	2.1
Pituitary gland	tissue	2.0
Smooth muscle	tissue	1.9	not detected
Thyroid gland	tissue	1.8	not detected
Placenta	tissue	1.7	not detected
Breast	tissue	1.6	not detected
Pons	tissue	1.5
Midbrain	tissue	1.5
Vagina	tissue	1.4	not detected
Hypothalamus	tissue	1.4
Superior colliculi	tissue	1.4
Liver	tissue	1.4	not detected
Periaqueductal gray	tissue	1.4
Esophagus	tissue	1.3	not detected
Putamen	tissue	1.3
Thalamus	tissue	1.3
Heart muscle	tissue	1.2	not detected
Septum	tissue	1.2
Ventral forebrain	tissue	1.1
Seminal vesicle	tissue	1.0	not detected
Hippocampal formation	tissue	1.0
Basal ganglia	tissue	0.9	not detected
Amygdala	tissue	0.7
Kidney	tissue	0.7	not detected
Olfactory bulb	tissue	0.7
Cerebral cortex	tissue	0.6	not detected
Parathyroid gland	tissue	0.6	not detected
Temporal cortex	tissue	0.6

Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — Parieto-temporal junction (white matter) (253.1), Temporal white matter (211.8), Corpus callosum, splenium (white matter) (178.6), Corpus callosum, genu (white matter) (165.9), Angular gyrus (white matter) (138.9).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): BCL6, FOXP1, SPI1, STAT1

miRNA regulators (miRDB)

Targeting CD22 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 40 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-1296-3P	99.72	64.04	636
HSA-MIR-4743-3P	99.62	68.12	2095
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-671-5P	99.52	67.11	1277
HSA-MIR-4434	99.10	67.01	1984
HSA-MIR-5703	99.10	67.09	2053
HSA-MIR-3154	98.94	66.55	1455
HSA-MIR-4755-3P	98.77	65.59	1915
HSA-MIR-7113-3P	98.75	65.71	1120
HSA-MIR-3945	98.68	64.21	553
HSA-MIR-1199-5P	98.44	66.51	829
HSA-MIR-6751-3P	98.44	66.35	835
HSA-MIR-3187-5P	98.36	65.74	1776
HSA-MIR-876-5P	97.99	68.49	1345
HSA-MIR-4736	97.96	65.89	1287
HSA-MIR-8089	97.74	66.21	1698

Functional genomics

gnomAD constraint: pLI 4.85e-06, LOEUF 0.639, missense Z 1.98 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000085219 — one region, missense o/e 0.88.

Literature-anchored findings (GeneRIF, showing 40)

• The Lyn/CD22/SHP-1 pathway is important in autoimmunity. Naive and tolerant B-cells differ in their calcium signaling in response to antigenic stimulation. (PMID:11826756)
• Disulfide bonds and the resulting 3D conformation of the CD22 molecules may have important roles in the difference of antigenicity of CD22 beta in B cells and basophils (PMID:11882357)
• ligand-binding of CD22 influences its intracellular signaling domain and is needed for inhibition of the B cell receptor signal (PMID:11994426)
• masking of the alpha2-6-linked sialic acid binding site of CD22 involves many cell surface sialoglycoproteins, without requiring specific ligand(s) and/or is mediated by secondary interactions with Sias on CD45 and sIgM (PMID:15240561)
• Aberrant CD22 expression is a useful marker for detection of monoclonal B cells admixed with numerous benign polyclonal B cells (PMID:15899772)
• decreased CD22 expression may be associated with the activation of B cells in Bullous pemphigoid (BP), but not associated with BP-specific antibody production (PMID:17055225)
• study showed that a synonymous SNP in CD22, c.2304C > A, was significantly associated with susceptibility to limited cutaneous systemic sclerosis (PMID:17493148)
• The results suggest that these two siglec proteins have evolved distinct endocytic mechanisms consistent with roles in cell signaling and innate immunity. (PMID:17562860)
• a decrease in CD22(+) B cells and increase in CD5(+)CD22(-) B cells play critical roles in the pathogenesis of RA mediated by the activation of B cells (PMID:17585360)
• These results indicate that the alpha2-6-sialylated 6-sulfo-LacNAc determinant serves as an endogenous ligand for human CD22 and suggest the possibility that 6-GlcNAc sulfation as well as alpha2-6-sialylation may regulate Siglec-2 functions in humans. (PMID:17728258)
• SAP is inducibly expressed in the human BJAB cells, and co-localizes and interacts with CD22. SAP binding to the inhibitory immunoreceptor CD22 regulates calcium mobilization in B cells. (PMID:19150402)
• Data show that anti-CD22 autoantibodies were positive in 80% of TSK/+ mice and in 22% of SSc patients. (PMID:19919568)
• The B-cell receptor IgM was found to be a major in situ trans ligand of CD22. (PMID:20172905)
• B cell surface receptors CD20 and CD22 are significantly affected in patients with SLE, pointing to their possible involvement in the aetiopathogenesis of the disease and in the regulatory mechanisms in response to the immune disturbance. (PMID:20726320)
• These striking findings implicate CD22DeltaE12 as a previously undescribed pathogenic mechanism in human B-precursor leukemia. (PMID:20841423)
• The efficacy of a ligand-targeting approach to B cell-specific depletion therapy for cancer may be the ability of CD22 to recycle and accumulate ligand-decorated cargo intracellularly, as an endocytic receptor. (PMID:21178016)
• Taken together, these results suggest that negative regulation of TLR signaling of B cells is an intrinsic property of CD22. (PMID:21178327)
• Studies showed the qualitative and quantitative expression of four target surface antigens, CD19, CD20, CD22, and CD33, for which MoAbs are currently available for clinical use, in ALL. (PMID:21348573)
• This CD22-targeted polymer carrier may be useful for siRNA delivery to lymphoma cells. (PMID:21629223)
• Results obtained through a large cohort of European caucasian patients with systemic sclerosis do not support the contribution of CD19, CD20, CD22, CD24 variants to the genetic susceptibility. (PMID:21961844)
• Our study implicates the CD22DeltaE12 genetic defect in the aggressive biology of relapsed or therapy-refractory paediatric B-lineage ALL. (PMID:22017452)
• Anti-CD22 recombinant immunotoxin moxetumomab pasudotox has activity in relapsed/refractory hairy cell leukemia. (PMID:22355053)
• The finding that CD22 is expressed on lung cancer cells is significant in revealing a heretofore unknown mechanism of tumorigenesis and metastasis (PMID:22986740)
• In the absence of functional CD22, B cells have a “hyperactivated” phenotype, CD22 dysfunction could contribute to the pathogenesis of autoimmune diseases. (Review) (PMID:23083346)
• study detected the expression of CD22 and CD72 on B cells of myasthenia gravis, compared to multiple sclerosis patient controls and healthy controls y (PMID:23184497)
• By using integrative genomics and analysing the relationships of COPD phenotypes with SNPs and gene expression in lung tissue, we identified CST3 and CD22 as potential causal genes for airflow obstruction. (PMID:25182044)
• These results suggest that the in vivo mechanism of non-ligand-blocking epratuzumab may, in part, involve the unmasking of CD22 to facilitate the trans-interaction of B cells with vascular endothelium. (PMID:25484043)
• MicroRNA-19a and CD22 Comprise a Feedback Loop for B Cell Response in Sepsis. (PMID:26017478)
• Anti-CD22-magnetic nanoparticles-doxorubicin inhibited the proliferation of Raji cells, significantly increased the uptake of doxorubicin, and induced apoptosis. (PMID:26379425)
• results demonstrate that loss of high affinity CD22 ligands on GC B-cells occurs in both mice and humans through alternative mechanisms, unmasking CD22 relative to naive and memory B-cells (PMID:26507663)
• Siglec-1 and Siglec-2 are potential biomarkers in autoimmune disease. (Review) (PMID:26752092)
• We aimed to screen exons 9-14 of the CD22 gene, which is a mutational hot spot region in B-precursor acute lymphoblastic leukemia (pre-B ALL) patients. Nine variants, of which two novel, were found. Novel variants were in introns 10 and 13. Gly745Asp (rs10406069) variant was missense and Cys790Arg (rs79438722) variant was silent. (PMID:27486888)
• Diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy reduced disease burden in a non-Hodgkin lymphoma mouse model. (PMID:27524505)
• This is the first time a NMR-based binding study of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt’s lymphoma Daudi cells has been described. (PMID:27808110)
• Conjugates of these multivalent ligands with auristatin and saporin toxins are efficiently internalized via hCD22 resulting in killing of B-cell lymphoma cells (PMID:28829594)
• Here the authors structurally characterize the ectodomain of CD22 and present its crystal structure with the bound therapeutic antibody epratuzumab, which gives insights into the mechanism of inhibition of B-cell activation. (PMID:28970495)
• hCD22 transgenic mice develop normal humoral responses in a peanut allergy oral sensitization model. Homing of B cells to Peyer’s patches was partially rescued by expression of hCD22 compared with CD22(-/-) B cells, although not to wild-type levels. (PMID:28972089)
• Authors semi-quantitatively classified baseline expression of sCD19 and sCD22 in a large cohort of pediatric B-ALL. Dim CD19 and negative CD22 cases were correlated with common genetic abnormalities. (PMID:30058145)
• CD22 plays a key role in affecting B cell responses to antigens and innate immune signals, and CD22-CD22L interactions are essential for maintaining self-tolerance. The ability of CD22 to regulate both B cell receptor and toll-like receptors represents an attractive therapeutic strategy for manipulating B cell responses in autoimmunity. (PMID:30323814)
• up-regulation of siglec-2 in tumor tissues could predict better overall survival (OS) in hepatocellular carcinoma patients. Mechanisms of siglec-2 in hepatocellular carcinoma (HCC) development need further research. (PMID:30355653)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	bckdhbl	ENSDARG00000093569
mus_musculus	Cd22	ENSMUSG00000030577
rattus_norvegicus	Cd22	ENSRNOG00000024000

Paralogs (16): SIGLEC1 (ENSG00000088827), SIGLEC8 (ENSG00000105366), CD33 (ENSG00000105383), SIGLEC6 (ENSG00000105492), MAG (ENSG00000105695), SIGLEC9 (ENSG00000129450), SIGLEC10 (ENSG00000142512), TMEM25 (ENSG00000149582), SIGLEC11 (ENSG00000161640), SIGLEC16 (ENSG00000161643), SIGLEC7 (ENSG00000168995), SIGLECL1 (ENSG00000179213), SIGLEC15 (ENSG00000197046), SIGLEC14 (ENSG00000254415), SIGLEC12 (ENSG00000254521), SIGLEC5 (ENSG00000268500)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:88322) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 46 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased B cell number	8
decreased marginal zone B cell number	5
decreased mature B cell number	4
abnormal B cell differentiation	3
abnormal B cell activation	3
abnormal immune system physiology	2
decreased IgM level	2
abnormal B cell physiology	2
increased anti-double stranded DNA antibody level	2
decreased B cell proliferation	2
abnormal B cell proliferation	2
increased B-1a cell number	2
abnormal mature B cell morphology	2
decreased memory B cell number	2
increased B cell apoptosis	2
abnormal B cell calcium ion homeostasis	2
increased monocyte cell number	1
abnormal immune system morphology	1
increased startle reflex	1
abnormal humoral immune response	1
arrested B cell differentiation	1
autoimmune response	1
premature death	1
abnormal immunoglobulin level	1
increased IgG level	1

+21 more (showing top 25).

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pan paniscus	Q9N1E5	99.9%	Diamond
Pan troglodytes	Q9N1E6	99.9%	Diamond
Gorilla gorilla gorilla	Q9N1E4	97.5%	Diamond
Pongo pygmaeus	Q9N1E3	92.5%	Diamond
Bos taurus	Q95132	64.4%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
FFAR1	protein-coding	2864
FFAR3	protein-coding	2865
MAG	protein-coding	4099
HAMP	protein-coding	57817
MIR5196	ncRNA	100847070
LSR	protein-coding	51599
USF2	protein-coding	7392
GPR42	protein-coding	2866

Protein

Protein identifiers

B-cell receptor CD22 — P20273 (reviewed: P20273)

Alternative names: B-lymphocyte cell adhesion molecule, Sialic acid-binding Ig-like lectin 2, T-cell surface antigen Leu-14

All UniProt accessions (14): P20273, A0A087WZQ4, M0QY05, M0QY14, M0QYP4, M0QZ01, M0QZP5, M0QZR7, M0R0R6, M0R1M2, M0R2M0, M0R2R8, M0R3H1, Q0EAF5

UniProt curated annotations — full annotation on UniProt →

Function. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced.

Subunit / interactions. Predominantly monomer of isoform CD22-beta. Also found as heterodimer of isoform CD22-beta and a shorter isoform. Interacts with PTPN6/SHP-1, LYN, SYK, PIK3R1/PIK3R2 and PLCG1 upon phosphorylation. Interacts with GRB2, INPP5D and SHC1 upon phosphorylation. May form a complex with INPP5D/SHIP, GRB2 and SHC1.

Subcellular location. Cell membrane.

Tissue specificity. B-lymphocytes.

Post-translational modifications. Phosphorylation of Tyr-762, Tyr-807 and Tyr-822 are involved in binding to SYK, GRB2 and SYK, respectively. Phosphorylation of Tyr-842 is involved in binding to SYK, PLCG2 and PIK3R1/PIK3R2. Phosphorylated on tyrosine residues by LYN.

Domain organisation. Contains 4 copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases.

Similarity. Belongs to the immunoglobulin superfamily. SIGLEC (sialic acid binding Ig-like lectin) family.

Isoforms (5)

UniProt ID	Names	Canonical?
P20273-1	CD22-beta	yes
P20273-2	CD22-alpha
P20273-3	3
P20273-4	4
P20273-5	5

RefSeq proteins (5): NP_001172028, NP_001172029, NP_001172030, NP_001265346, NP_001762* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013162	CD80_C2-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR056386	Ig_CD22	Domain

Pfam: PF08205, PF13895, PF13927, PF24518

UniProt features (110 total): strand 40, glycosylation site 11, helix 9, disulfide bond 8, sequence variant 8, domain 7, modified residue 7, splice variant 6, short sequence motif 4, topological domain 2, sequence conflict 2, turn 2, signal peptide 1, chain 1, binding site 1, transmembrane region 1

Structure

Experimental structures (PDB)

7 structures by resolution:

PDB	Title	Method	Resolution (Å)
5VKJ	Crystal structure of human CD22 Ig domains 1-3	X-RAY DIFFRACTION	2.12
5VKM	Crystal structure of human CD22 Ig domains 1-3 in complex with alpha 2-6 sialyllactose	X-RAY DIFFRACTION	2.2
7O52	CD22 d6-d7 in complex with Fab m971	X-RAY DIFFRACTION	2.41
9ROB	Crystal structure of human CD22 Ig domains 1-3 in complex with modified sialoside 1B	X-RAY DIFFRACTION	2.7
9RM3	Crystal structure of human CD22 Ig domains 1-3 in complex with modified sialoside 17	X-RAY DIFFRACTION	2.86
5VL3	CD22 d1-d3 in complex with therapeutic Fab Epratuzumab	X-RAY DIFFRACTION	3.1
9RO7	Crystal structure of human CD22 Ig domains 1-3 in complex with modified sialoside 7-012	X-RAY DIFFRACTION	3.15

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P20273-F1	79.33	0.51

Antibody-complex structures (SAbDab)

2 antibodies co-crystallized with this protein: 5VL3, 7O52

Human Protein Atlas

Protein class: CD markers, Predicted membrane proteins, Predicted intracellular proteins, Plasma proteins, FDA approved drug targets, Biotech drugs

Protein evidence: Evidence at protein level

Antibody reliability (HPA): IH enhanced

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1)

Position	Role
120	N-acetylneuraminate

Post-translational modifications (7)

Type	Positions
Phosphoserine	725, 726, 729
Phosphotyrosine	762, 807, 822, 842

Disulfide bonds (8)

Type	Positions
Disulfide bond	39–167, 44–102, 161–219, 265–309, 353–396, 442–484, 529–571, 616–659

Glycosylation sites (11)

Type	Positions
N-linked (glcnac…) asparagine	67, 101, 112, 135, 164, 231, 363, 445, 479, 574, 634

Function

Pathways and Gene Ontology

Reactome pathways

2 curated (TAS) of 6; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

6 pathways:

ID	Pathway	Evidence
R-HSA-5690714	CD22 mediated BCR regulation	curated
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	curated
R-HSA-1280218	Adaptive Immune System	—
R-HSA-983695	Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	electronic
R-HSA-168256	Immune System	—
R-HSA-983705	Signaling by the B Cell Receptor (BCR)	—

MSigDB gene sets: 310 (showing top): PID_BCR_5PATHWAY, GOBP_REGULATION_OF_B_CELL_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, MODULE_52, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_REGULATION_OF_CALCIUM_MEDIATED_SIGNALING, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_B_CELL_ACTIVATION, GOBP_NEGATIVE_REGULATION_OF_PRODUCTION_OF_MOLECULAR_MEDIATOR_OF_IMMUNE_RESPONSE, MODULE_45, MODULE_64, GOBP_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, GOCC_CELL_SURFACE, GOBP_B_CELL_PROLIFERATION

GO Biological Process (10): negative regulation of immunoglobulin production (GO:0002638), cell adhesion (GO:0007155), regulation of endocytosis (GO:0030100), regulation of B cell proliferation (GO:0030888), B cell activation (GO:0042113), regulation of immune response (GO:0050776), negative regulation of calcium-mediated signaling (GO:0050849), negative regulation of B cell receptor signaling pathway (GO:0050859), negative regulation of immune system process (GO:0002683), negative regulation of signal transduction (GO:0009968)

GO Molecular Function (7): IgM binding (GO:0001791), signaling receptor binding (GO:0005102), protein phosphatase binding (GO:0019903), carbohydrate binding (GO:0030246), sialic acid binding (GO:0033691), CD4 receptor binding (GO:0042609), protein binding (GO:0005515)

GO Cellular Component (9): cytoplasm (GO:0005737), early endosome (GO:0005769), plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), membrane (GO:0016020), neuronal cell body membrane (GO:0032809), recycling endosome (GO:0055037), extracellular exosome (GO:0070062)

Reactome top-level categories

3 top-level categories:

Category	Pathways
Adaptive Immune System	2
Signaling by the B Cell Receptor (BCR)	2
Immune System	1

GO top-level categories

45 GO namespaces:

Category	Terms
cellular anatomical structure	3
regulation of immune system process	2
binding	2
endosome	2
immunoglobulin production	1
regulation of immunoglobulin production	1
negative regulation of production of molecular mediator of immune response	1
cellular process	1
endocytosis	1
regulation of transport	1
regulation of cellular component organization	1
B cell proliferation	1
regulation of lymphocyte proliferation	1
regulation of B cell activation	1
lymphocyte activation	1
immune response	1
regulation of response to stimulus	1
calcium-mediated signaling	1
regulation of calcium-mediated signaling	1
negative regulation of intracellular signal transduction	1
B cell receptor signaling pathway	1
regulation of B cell receptor signaling pathway	1
negative regulation of antigen receptor-mediated signaling pathway	1
immune system process	1
negative regulation of biological process	1
signal transduction	1
regulation of signal transduction	1
negative regulation of cell communication	1
negative regulation of signaling	1
negative regulation of response to stimulus	1
immunoglobulin binding	1
protein binding	1
phosphatase binding	1
carboxylic acid binding	1
carbohydrate derivative binding	1
signaling receptor binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1
neuronal cell body	1
cell body membrane	1
extracellular vesicle	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 6 of 26 annotations. The rest are phylogenetic / computational / electronic (IEA).

6 experimentally-supported GO terms:

GO term	NS	Evidence
B cell activation	BP	direct assay
negative regulation of B cell receptor signaling pathway	BP	direct assay
regulation of endocytosis	BP	direct assay
early endosome	CC	direct assay
extracellular exosome	CC	high-throughput assay
recycling endosome	CC	direct assay

Protein interactions and networks

STRING

showing 15 of 1,766 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CD22	CD19	P15391	921
CD22	CD79A	P11912	855
CD22	FFAR3	O14843	837
CD22	BCR	P11274	809
CD22	CD5	P06127	800
CD22	MME	P08473	800
CD22	FFAR1	O14842	777
CD22	DNTT	P04053	768
CD22	CD79B	P40259	768
CD22	FFAR2	O15552	767
CD22	GALR2	O43603	760
CD22	CD38	P28907	759
CD22	GALR1	P47211	758
CD22	GPR42	O15529	757
CD22	GAL	P22466	755

IntAct

Human interaction partners of CD22 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

8 partners by confidence:

Partner	Interaction type	MIscore	Records
SYK	physical association	0.620	1
PTPN6	association	0.500	3
LYN	association	0.500	2
PLCG1	association	0.500	2
PTPRC	physical association	0.400	1
CFTR	physical association	0.370	1
ECE1	physical association	0.370	1
S100A7	association	0.350	1

BioGRID (44 interactions; top human partners by supporting records): PTPN6 (Affinity Capture-Western; 6 records), GRB2 (Affinity Capture-Western; 3 records), INPP5D (Affinity Capture-Western; 2 records), LYN (Biochemical Activity; 2 records), SHC1 (Affinity Capture-Western; 2 records), ANKRD46 (Two-hybrid), AP2A1 (Affinity Capture-Western), AP2M1 (Two-hybrid), ATG16L1 (Affinity Capture-MS), BIRC5 (Negative Genetic), CAMK1G (Positive Genetic), CAMK2B (Negative Genetic), CD19 (Affinity Capture-Western), CFTR (PCA), CPA4 (Affinity Capture-MS)

SIGNOR signaling

3 signaling interactions:

A	Effect	B	Mechanism
LYN	“down-regulates activity”	CD22	phosphorylation
CD22	“up-regulates activity”	SH2B1	binding
ST6GAL1	“down-regulates activity”	CD22	glycosylation

Ligand–receptor pairs (CellPhoneDB) (2)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

2 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
BCR;PTPRC;CD22		Signaling by Galectin
PTPRC	receptor

Disease & clinical

Genetic variants

Variant evidence for CD22: 149 ClinVar records (1 pathogenic / likely pathogenic); 1 GWAS association. Per-variant detail is on Sugi Variant.

ClinVar

149 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	108
Likely benign	18
Benign	4

Top pathogenic / likely-pathogenic (1)

Showing all 1 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
3242311	GRCh37/hg19 19q13.11-13.12(chr19:35223021-36895699)x1	Pathogenic	criteria provided, single submitter	1

Per-variant reference — Sugi Variant

Explore CD22’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 22 predictions of 1,527):

Position(s)	Effect	Δscore	Sites
19:35336128	acceptor_gain	1.0000
19:35337951	donor_gain	1.0000
19:35338306	donor_gain	1.0000
19:35340879–35340880	acceptor_loss	1.0000	5
19:35344824	acceptor_gain	1.0000
19:35344926–35344927	donor_loss	1.0000	4
19:35345127–35345128	donor_loss	1.0000	4
19:35345600	acceptor_loss	1.0000
19:35329231–35329232	donor_loss	0.9900	3
19:35332576	acceptor_gain	0.9900

AlphaMissense

872 missense substitutions predicted likely pathogenic (of 5,589 scored), across 276 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
N400	8	0.940	0.994
D113	8	0.868	0.935
C529	7	0.976	0.991
C442	7	0.975	0.987
C353	7	0.972	0.988
C571	7	0.971	0.986
C219	7	0.964	0.983
C161	7	0.961	0.986
C396	7	0.960	0.983
C484	7	0.960	0.977
C102	7	0.959	0.980
C659	7	0.957	0.987
C616	7	0.954	0.977
W543	7	0.947	0.992
C44	7	0.946	0.974
C167	7	0.946	0.963
W366	7	0.931	0.986
N575	7	0.929	0.990
W35	7	0.922	0.992
C265	7	0.922	0.957

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Prostate Adenocarcinoma (TCGA)	favorable	0.000977

Disease associations

OMIM: gene MIM:107266 | disease phenotypes:

GWAS associations

1 associations:

Study	Trait	p-value
GCST90002404_553	Red cell distribution width	7e-11

EFO canonical traits (from GWAS)

1 canonical traits:

EFO ID	Trait name
EFO:0009188	Red cell distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3218 (SINGLE PROTEIN)

Drugs by curated mechanism of action (ChEMBL)

Drugs whose curated ChEMBL mechanism of action targets the CD22 protein itself — single-protein targets only (drugs acting on a protein family or complex that merely includes it are excluded). Includes antibodies and oligonucleotides that bioactivity screening does not capture.

13 curated-mechanism drugs:

Drug	Modality	Max phase
INOTUZUMAB OZOGAMICIN	Antibody drug conjugate	4
MOXETUMOMAB PASUDOTOX	Antibody drug conjugate	4
BECTUMOMAB	Antibody	3
EPRATUZUMAB	Antibody	3
EPRATUZUMAB 90Y	Antibody	3
INOTUZUMAB	Antibody	3
BL22	Unknown	2
PINATUZUMAB VEDOTIN	Antibody drug conjugate	2
YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN	Antibody	2
EPRATUZUMAB-CYS-TESIRINE	Antibody drug conjugate	1
MONO-DGA-RFB4	Unknown	1
YTTRIUM Y 90 EPRATUZUMAB	Antibody	1
IMMURAIT-LL2	Unknown	—

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — CD molecules

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
inotuzumab ozogamicin	Binding	9.7	pKd
moxetumomab pasudotox	Binding	8.22	pKd

Binding affinities (BindingDB)

54 measured of 54 human assays (54 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL5184174	IC50	0.32 nM
CHEMBL5185214	IC50	0.39 nM
CHEMBL5197497	IC50	0.41 nM
(2R,4S,5R,6R)-2-(biphenyl-4-ylmethoxy)-6-((1R,2R)-1,2-dihydroxy-3-(2-(4’-hydroxybiphenyl-4-yl)acetamido)propyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid	IC50	70 nM
benzyl 3,5,9-trideoxy-5-glycolamido-9-(4’-hydroxy-4-biphenyl)acetamido-D-glycero-alpha-D-galacto-2-nonulopyranosidonic acid	IC50	130 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(2’-hydroxy-4-biphenyl)-methylamino-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	230 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(4-hydroxy-4-biphenyl)-methylamino-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	240 nM
CHEMBL4788433	KD	335 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(4beta-hydroxy-4-biphenyl-carboxamido)-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	400 nM
CHEMBL4780037	KD	458 nM
p-Methoxyphenyl (9-(4-biphenyl)methylamino-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	470 nM
CHEMBL4760637	KD	620 nM
CHEMBL4739978	KD	628 nM
CHEMBL4761167	KD	740 nM
CHEMBL4752379	KD	766 nM
Benzyl 3,5,9-trideoxy-5-glycolamido-9-(4’-hydroxy-4-biphenyl)methylamino-D-glycero-alpha-D-galacto-2-nonulopyranosidonic acid	IC50	820 nM
CHEMBL4783164	KD	860 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(4’-hydroxy-4-biphenyl)-acetamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	900 nM
CHEMBL4797221	KD	952 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(2-naphtyl)-acetamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	1000 nM
p-Methoxyphenyl (9-(4-biphenylcarboxamido)-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	1100 nM
(4-Biphenyl)methyl 3,5,9-trideoxy-5-glycolamido-9-(4’-hydroxy-4-biphenyl)methylamino-D-glycero-alpha-D-galacto-2-nonulopyranosidonic acid	IC50	1120 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(3’-hydroxy-4-biphenyl)-methylamino-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	1730 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(4’-methoxy-4-biphenyl)-methylamino-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	1760 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(2-naphtamido)-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	2600 nM
p-Methoxyphenyl (9-(4-biphenyl)acetamido-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	3700 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(3’-hydroxy-4-biphenyl)-acetamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	4300 nM
p-Methoxyphenyl (9-2(4-biphenyl)ethylamino-3,5, 9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	5480 nM
p-Methoxyphenyl (9-4(4-biphenyl)butylamino-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	6220 nM
p-Methoxyphenyl (9-(3beta-carboxy-4-biphenylcarboxamido)-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	7130 nM
p-Methoxyphenyl (9-(3’-carboxy-4-biphenyl)methylamino-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	7480 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(3-(p-hydroxyphenyl)propionamido)-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	7650 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-diphenylacetamido-D-glycero-D-alpha-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	8850 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(4’-methyl-4-biphenyl)-methylamino-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	9830 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(3-phenylpropionamido)-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	10400 nM
p-Methoxyphenyl (9-cyclohexanecarboxamido-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	16000 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(4(1-pyrenyl)butanoylamino)-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	21100 nM
CHEMBL5186305	IC50	24000 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-(3,5-dimethoxybenzyl)amino-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	24800 nM
p-Methoxyphenyl (9-cyclohexylmethylamino-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	37700 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-hexanamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	40800 nM
p-Methoxyphenyl (9-(4’-carboxy-4-biphenyl)methylamino-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	43000 nM
p-Methoxyphenyl (3,5,9-trideoxy-9-(4’-trifluromethyl-4-biphenyl)methylamino-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	45000 nM
p-Methoxyphenyl (9-(4beta-carboxy-4-biphenylcarboxamido)-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	73200 nM
p-Methoxyphenyl (9-amino-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	85000 nM
p-Methoxyphenyl (9-(5-chloro-2-hydroxybenzamido)-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonicacid)-(2->6)-beta-D-galactopyranoside	IC50	116000 nM
p-Methoxyphenyl (9-benzylamino-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	123000 nM
p-Methoxyphenyl (9-benzamido-3,5,9-trideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	125000 nM
p-Methoxyphenyl (3,5,9-trideoxy-5-glycolamido-9-nicotinoylamino-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	132000 nM
p-Methoxyphenyl (3,5-dideoxy-5-glycolamido-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2->6)-beta-D-galactopyranoside	IC50	148000 nM

ChEMBL bioactivities

37 potent at pChembl≥5 of 48 total, top 36 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.49	IC50	0.32	nM	CHEMBL5184174
9.41	IC50	0.39	nM	CHEMBL5185214
9.39	IC50	0.41	nM	CHEMBL5197497
7.16	IC50	70	nM	CHEMBL1684361
6.89	IC50	130	nM	CHEMBL1684360
6.64	IC50	230	nM	CHEMBL511111
6.62	IC50	240	nM	CHEMBL502862
6.47	Kd	335	nM	CHEMBL4788433
6.40	IC50	400	nM	CHEMBL509768
6.34	Kd	458	nM	CHEMBL4780037
6.33	IC50	470	nM	CHEMBL509633
6.28	IC50	530	nM	CHEMBL502862
6.21	Kd	620	nM	CHEMBL4760637
6.20	Kd	628	nM	CHEMBL4739978
6.13	Kd	740	nM	CHEMBL4761167
6.12	Kd	766	nM	CHEMBL4752379
6.09	IC50	820	nM	CHEMBL1684363
6.07	Kd	860	nM	CHEMBL4783164
6.05	IC50	900	nM	CHEMBL501599
6.02	Kd	952	nM	CHEMBL4797221
6.00	IC50	1000	nM	CHEMBL502788
5.96	IC50	1100	nM	CHEMBL503830
5.95	IC50	1120	nM	CHEMBL1684364
5.76	IC50	1730	nM	CHEMBL505326
5.75	IC50	1760	nM	CHEMBL504222
5.66	IC50	2200	nM	CHEMBL5197497
5.58	IC50	2600	nM	CHEMBL467951
5.43	IC50	3700	nM	CHEMBL451427
5.37	IC50	4300	nM	CHEMBL446730
5.26	IC50	5480	nM	CHEMBL453397
5.21	IC50	6220	nM	CHEMBL448298
5.15	IC50	7130	nM	CHEMBL508909
5.13	IC50	7480	nM	CHEMBL500461
5.12	IC50	7650	nM	CHEMBL499744
5.05	IC50	8850	nM	CHEMBL510261
5.01	IC50	9830	nM	CHEMBL460576

PubChem BioAssay actives

37 with measured affinity, of 117 total; 34 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
sodium (2R,4S,5R,6R)-5-acetamido-2-[3-(2-benzamidoethylsulfanyl)propoxy]-6-[(1R,2R)-1,2-dihydroxy-3-[(4-phenylbenzoyl)amino]propyl]-4-hydroxyoxane-2-carboxylate	1863566: Inhibition hFc tagged CD22 incubated for 4 hrs by ELISA	ic50	0.0003	uM
disodium;(2R,4S,5R,6R)-5-acetamido-2-[3-[2-[[4-[2-[3-[(2R,4S,5R,6R)-5-acetamido-2-carboxylato-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxypropylsulfanyl]ethylcarbamoyl]benzoyl]amino]ethylsulfanyl]propoxy]-6-[(1R,2R)-1,2-dihydroxy-3-[(4-phenylbenzoyl)amino]propyl]-4-hydroxyoxane-2-carboxylate	1863566: Inhibition hFc tagged CD22 incubated for 4 hrs by ELISA	ic50	0.0004	uM
disodium;(2R,4S,5R,6R)-5-acetamido-2-[3-[2-[[4-[2-[3-[(2R,4S,5R,6R)-5-acetamido-2-carboxylato-6-[(1R,2R)-1,2-dihydroxy-3-[(4-phenylbenzoyl)amino]propyl]-4-hydroxyoxan-2-yl]oxypropylsulfanyl]ethylcarbamoyl]benzoyl]amino]ethylsulfanyl]propoxy]-6-[(1R,2R)-1,2-dihydroxy-3-[(4-phenylbenzoyl)amino]propyl]-4-hydroxyoxane-2-carboxylate	1863566: Inhibition hFc tagged CD22 incubated for 4 hrs by ELISA	ic50	0.0004	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[2-[4-(4-hydroxyphenyl)phenyl]acetyl]amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[(4-phenylphenyl)methoxy]oxane-2-carboxylic acid	578486: Antagonist activity at human CD22 after 1 hr by competitive ELISA	ic50	0.0700	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[2-[4-(4-hydroxyphenyl)phenyl]acetyl]amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-phenylmethoxyoxane-2-carboxylic acid	578486: Antagonist activity at human CD22 after 1 hr by competitive ELISA	ic50	0.1300	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[4-(2-hydroxyphenyl)phenyl]methylamino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	0.2300	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[4-(4-hydroxyphenyl)phenyl]methylamino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	0.2400	uM
sodium (2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[2-[4-(4-hydroxyphenyl)phenyl]acetyl]amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-(4-phenyltriazol-1-yl)oxane-2-carboxylate	1705724: Binding affinity to recombinant human CD22d1-3-Fc expressed in 293T cells by surface plasmon resonance assay	kd	0.3350	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[4-(4-hydroxyphenyl)benzoyl]amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	0.4000	uM
sodium (2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[2-[4-(4-hydroxyphenyl)phenyl]acetyl]amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-phenylmethoxyoxane-2-carboxylate	1705724: Binding affinity to recombinant human CD22d1-3-Fc expressed in 293T cells by surface plasmon resonance assay	kd	0.4580	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[(4-phenylphenyl)methylamino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	0.4700	uM
sodium (2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[2-[4-(4-hydroxyphenyl)phenyl]acetyl]amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[4-(4-phenylphenyl)triazol-1-yl]oxane-2-carboxylate	1705724: Binding affinity to recombinant human CD22d1-3-Fc expressed in 293T cells by surface plasmon resonance assay	kd	0.6200	uM
sodium (2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[2-[4-(4-hydroxyphenyl)phenyl]acetyl]amino]propyl]-2-[(4-ethynylphenyl)methoxy]-4-hydroxy-5-[(2-hydroxyacetyl)amino]oxane-2-carboxylate	1705724: Binding affinity to recombinant human CD22d1-3-Fc expressed in 293T cells by surface plasmon resonance assay	kd	0.6280	uM
sodium (2R,4S,5R,6R)-2-[[4-[1-[2-[2-[2-[2-[5-[(3aR,4R,6aS)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]phenyl]methoxy]-6-[(1R,2R)-1,2-dihydroxy-3-[[2-[4-(4-hydroxyphenyl)phenyl]acetyl]amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]oxane-2-carboxylate	1705724: Binding affinity to recombinant human CD22d1-3-Fc expressed in 293T cells by surface plasmon resonance assay	kd	0.7400	uM
sodium (2R,4S,5R,6R)-2-[4-(cyclohexylmethyl)triazol-1-yl]-6-[(1R,2R)-1,2-dihydroxy-3-[[2-[4-(4-hydroxyphenyl)phenyl]acetyl]amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]oxane-2-carboxylate	1705724: Binding affinity to recombinant human CD22d1-3-Fc expressed in 293T cells by surface plasmon resonance assay	kd	0.7660	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[4-(4-hydroxyphenyl)phenyl]methylamino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-phenylmethoxyoxane-2-carboxylic acid	578486: Antagonist activity at human CD22 after 1 hr by competitive ELISA	ic50	0.8200	uM
sodium (2R,4S,5R,6R)-2-[4-(cyclohexylmethoxy)triazol-1-yl]-6-[(1R,2R)-1,2-dihydroxy-3-[[2-[4-(4-hydroxyphenyl)phenyl]acetyl]amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]oxane-2-carboxylate	1705724: Binding affinity to recombinant human CD22d1-3-Fc expressed in 293T cells by surface plasmon resonance assay	kd	0.8600	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[2-[4-(4-hydroxyphenyl)phenyl]acetyl]amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	0.9000	uM
sodium (2R,4S,5R,6R)-2-(4-benzyltriazol-1-yl)-6-[(1R,2R)-1,2-dihydroxy-3-[[2-[4-(4-hydroxyphenyl)phenyl]acetyl]amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]oxane-2-carboxylate	1705724: Binding affinity to recombinant human CD22d1-3-Fc expressed in 293T cells by surface plasmon resonance assay	kd	0.9520	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[(2-naphthalen-2-ylacetyl)amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	1.0000	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[(4-phenylbenzoyl)amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	1.1000	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[4-(4-hydroxyphenyl)phenyl]methylamino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[(4-phenylphenyl)methoxy]oxane-2-carboxylic acid	578486: Antagonist activity at human CD22 after 1 hr by competitive ELISA	ic50	1.1200	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[4-(3-hydroxyphenyl)phenyl]methylamino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	1.7300	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[4-(4-methoxyphenyl)phenyl]methylamino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	1.7600	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-(naphthalene-2-carbonylamino)propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	2.6000	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[2-(4-phenylphenyl)acetyl]amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	3.7000	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[2-[4-(3-hydroxyphenyl)phenyl]acetyl]amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	4.3000	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[2-(4-phenylphenyl)ethylamino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	5.4800	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[4-(4-phenylphenyl)butylamino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	6.2200	uM
(2R,4S,5R,6R)-6-[(1R,2R)-3-[[4-(3-carboxyphenyl)benzoyl]amino]-1,2-dihydroxypropyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	7.1300	uM
(2R,4S,5R,6R)-6-[(1R,2R)-3-[[4-(3-carboxyphenyl)phenyl]methylamino]-1,2-dihydroxypropyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	7.4800	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[3-(4-hydroxyphenyl)propanoylamino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	7.6500	uM
(2R,4S,5R,6R)-6-[(1R,2R)-3-[(2,2-diphenylacetyl)amino]-1,2-dihydroxypropyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	8.8500	uM
(2R,4S,5R,6R)-6-[(1R,2R)-1,2-dihydroxy-3-[[4-(4-methylphenyl)phenyl]methylamino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	389258: Binding affinity to biotinylated human CD22-human IgG1 chimeric protein expressed in mouse J558LST6 cells by flow cytometry	ic50	9.8300	uM

CTD chemical–gene interactions

53 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tretinoin	affects expression, increases expression	3
Estradiol	increases expression, affects binding	2
Formaldehyde	decreases expression	2
Aflatoxin B1	increases methylation, decreases methylation	2
aristolochic acid I	increases expression	1
sotorasib	affects cotreatment, decreases expression	1
dicrotophos	increases expression	1
methyleugenol	increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
kojic acid	decreases expression	1
terbufos	decreases methylation	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	increases expression	1
sulforaphane	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	increases expression	1
perfluorooctanoic acid	decreases expression	1
ochratoxin A	increases acetylation, increases expression	1
aflatoxin B2	increases methylation	1
bryostatin 1	increases expression	1
tamibarotene	affects expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
perfluorohexanesulfonic acid	decreases expression	1
abrine	increases expression	1
jinfukang	affects cotreatment, increases expression	1

ChEMBL screening assays

16 unique, capped per target: 15 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1169089	Binding	Binding affinity to human SIGLEC2 by saturation transfer difference-titration assay	Synthesis and binding analysis of unique AG2 pentasaccharide to human Siglec-2 using NMR techniques. — *Bioorg Med Chem*
CHEMBL1686886	Functional	Antagonist activity at human CD22 after 1 hr by competitive ELISA	CD22-antagonists with nanomolar potency: the synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffold. — *Bioorg Med Chem*

Cellosaurus cell lines

5 cell lines: 3 cancer cell line, 1 spontaneously immortalized cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1GD	Abcam Raji CD22 KO	Cancer cell line	Male
CVCL_E6PB	Genomeditech CHO-K1 H_CD22	Spontaneously immortalized cell line	Female
CVCL_F1SV	HyCyte Ramos KO-hCD22	Cancer cell line	Male
CVCL_F1TV	HyCyte THP-1 KO-hCD22	Cancer cell line	Male
CVCL_UE23	293T human CD22	Transformed cell line	Female

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

12 trials:

NCT	Phase	Status	Title
NCT03414970	Phase 3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	Phase 2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	Phase 2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	Phase 1/2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	Phase 1/2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	Early Phase 1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	Early Phase 1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT07628634	Early Phase 1	RECRUITING	Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
NCT01208974	Not specified	COMPLETED	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for CD22 across ~30M SureChEMBL compounds — explore on Sugi Predict.